Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) Profit After Tax (2016 - 2025)

Purple Biotech has reported Profit After Tax over the past 6 years, most recently at -$37.5 million for Q4 2022.

  • Quarterly Profit After Tax fell 833.98% to -$37.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$36.4 million through Dec 2022, down 298.52% year-over-year, with the annual reading at -$26.5 million for FY2025, 263.95% down from the prior year.
  • Profit After Tax was -$37.5 million for Q4 2022 at Purple Biotech, down from $4.8 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $6.4 million in Q1 2021 and troughed at -$37.5 million in Q4 2022.
  • The 5-year median for Profit After Tax is $3.1 million (2021), against an average of -$2.0 million.
  • Year-over-year, Profit After Tax surged 2079.07% in 2021 and then tumbled 833.98% in 2022.
  • A 5-year view of Profit After Tax shows it stood at -$386000.0 in 2018, then tumbled by 751.55% to -$3.3 million in 2019, then surged by 92.15% to -$258000.0 in 2020, then surged by 2079.07% to $5.1 million in 2021, then tumbled by 833.98% to -$37.5 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Profit After Tax are -$37.5 million (Q4 2022), $4.8 million (Q3 2022), and $3.6 million (Q2 2022).